844 related articles for article (PubMed ID: 28810803)
1. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
2. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
3. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
4. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
6. Driving cars to the clinic for solid tumors.
Castellarin M; Watanabe K; June CH; Kloss CC; Posey AD
Gene Ther; 2018 Jun; 25(3):165-175. PubMed ID: 29880908
[TBL] [Abstract][Full Text] [Related]
7. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
9. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
10. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
13. Driving T-cell immunotherapy to solid tumors.
Garber K
Nat Biotechnol; 2018 Mar; 36(3):215-219. PubMed ID: 29509745
[No Abstract] [Full Text] [Related]
14. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.
Chung H; Jung H; Noh JY
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830003
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.
Kiesgen S; Chicaybam L; Chintala NK; Adusumilli PS
J Thorac Oncol; 2018 Jan; 13(1):16-26. PubMed ID: 29107016
[TBL] [Abstract][Full Text] [Related]
16. The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.
Hombach AA; Holzinger A; Abken H
Curr Mol Med; 2013 Aug; 13(7):1079-88. PubMed ID: 23116267
[TBL] [Abstract][Full Text] [Related]
17. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS
Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494
[TBL] [Abstract][Full Text] [Related]
18. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
19. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell therapy: 25years in the making.
Gill S; Maus MV; Porter DL
Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]